ATE526421T1 - Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration - Google Patents

Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration

Info

Publication number
ATE526421T1
ATE526421T1 AT06735123T AT06735123T ATE526421T1 AT E526421 T1 ATE526421 T1 AT E526421T1 AT 06735123 T AT06735123 T AT 06735123T AT 06735123 T AT06735123 T AT 06735123T AT E526421 T1 ATE526421 T1 AT E526421T1
Authority
AT
Austria
Prior art keywords
reagents
diagnosis
treatment
age
methods
Prior art date
Application number
AT06735123T
Other languages
German (de)
English (en)
Inventor
Gregory S Hageman
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526421(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of ATE526421T1 publication Critical patent/ATE526421T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06735123T 2005-02-14 2006-02-14 Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration ATE526421T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65307805P 2005-02-14 2005-02-14
US71550305P 2005-09-09 2005-09-09
US71786105P 2005-09-16 2005-09-16
US73569705P 2005-11-09 2005-11-09
PCT/US2006/005313 WO2006088950A2 (en) 2005-02-14 2006-02-14 Methods and reagents for treatment and diagnosis of age-related macular degeneration

Publications (1)

Publication Number Publication Date
ATE526421T1 true ATE526421T1 (de) 2011-10-15

Family

ID=36917017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06735123T ATE526421T1 (de) 2005-02-14 2006-02-14 Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration

Country Status (12)

Country Link
US (8) US8088579B2 (enExample)
EP (5) EP2357257B1 (enExample)
JP (4) JP2008529536A (enExample)
KR (2) KR20130100207A (enExample)
CN (1) CN103920142A (enExample)
AT (1) ATE526421T1 (enExample)
AU (1) AU2006214320C1 (enExample)
CA (1) CA2597411C (enExample)
IL (2) IL185219A (enExample)
MX (1) MX2007009565A (enExample)
NZ (2) NZ608860A (enExample)
WO (1) WO2006088950A2 (enExample)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
WO2006062716A2 (en) * 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
EP2357257B1 (en) 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
CA2599080A1 (en) 2005-03-04 2006-09-14 Duke University Genetic variants increase the risk of age-related macular degeneration
AU2006220604A1 (en) * 2005-03-07 2006-09-14 Board Of Regents, The University Of Texas System Diagnostic and therapeutic target for macular degeneration
ES2548700T3 (es) * 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
WO2007032876A2 (en) * 2005-09-09 2007-03-22 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
US20070149616A1 (en) * 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
WO2007120975A2 (en) 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
NZ574046A (en) 2006-07-13 2012-09-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
EP2054728A2 (en) * 2006-08-23 2009-05-06 University of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
CN106084054A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
WO2008110283A2 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
WO2008110828A1 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
AU2008251943B2 (en) * 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
WO2008137236A2 (en) * 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
CA2705500A1 (en) * 2007-05-11 2008-11-20 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
US20090203001A1 (en) * 2007-08-24 2009-08-13 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
CA2704809A1 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
EP2283163B1 (en) * 2008-04-18 2015-07-08 Tufts Medical Center Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009134709A2 (en) * 2008-04-28 2009-11-05 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
US20100145223A1 (en) * 2008-11-26 2010-06-10 Duke University Peripheral Reticular Pigmentary Change and Age-Related Macular Degeneration
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
GB0911717D0 (en) * 2009-07-06 2009-08-19 Ucl Business Plc Method
EP2963128A1 (en) 2009-07-10 2016-01-06 The Regents of the University of Michigan Compositions and methods for diagnosing and treating macular degeneration
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
AT514675B1 (de) * 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
US8236570B2 (en) * 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
FR2952539B1 (fr) * 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
EP2533797A1 (en) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Complement factor h for oxidative stress disease conditions
AU2011253481A1 (en) * 2010-05-12 2013-01-10 Steven E. Schutzer Diagnostic markers for neuropsychiatric disease
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
EP2585110A4 (en) 2010-06-22 2014-01-22 Univ Colorado Regents ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
WO2012051462A2 (en) * 2010-10-14 2012-04-19 Sequenom, Inc. Complement factor h copy number variants found in the rca locus
PL2635704T3 (pl) * 2010-11-01 2017-09-29 F.Hoffmann-La Roche Ag Przewidywanie progresji do zaawansowanego zwyrodnienia plamki żółtej związanego z wiekiem z zastosowaniem wskaźnika poligenicznego
WO2012112955A2 (en) * 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing iga nephropathy
CN103874526A (zh) * 2011-04-29 2014-06-18 犹他大学研究基金会 预测补体介导的疾病的发展的方法
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
WO2014043558A1 (en) * 2012-09-14 2014-03-20 University Of Utah Research Foundation Methods of predicting the development of amd based on chromosome 1 and chromosome 10
CA2891673C (en) 2012-11-15 2025-10-07 Apellis Pharmaceuticals Inc Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
PL2968457T3 (pl) 2013-03-14 2018-12-31 Baxalta Incorporated Czynnik h do transplantacji
JP6484215B2 (ja) * 2013-03-14 2019-03-13 バクスアルタ インコーポレイテッド 関節リウマチの治療のためのｈ因子
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
WO2014197885A2 (en) * 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
WO2015023920A1 (en) 2013-08-15 2015-02-19 Schutzer Steven E Diagnostic markers for multiple sclerosis
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
RU2727411C2 (ru) 2015-09-24 2020-07-21 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиция и способ для лечения заболевания, опосредованного комплементом
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
JP7199966B2 (ja) 2015-12-23 2023-01-06 ソルボンヌ ウニベルシテ ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用
FR3046355A1 (fr) * 2015-12-30 2017-07-07 Lab Francais Du Fractionnement Fragments du facteur h pour son utilisation comme agent anti-angiogenique
MX392422B (es) * 2016-06-21 2025-03-24 Orion Ophthalmology LLC Derivados de prolinamida heterociclica
CA3047893C (en) * 2016-12-22 2022-11-15 Daiichi Sankyo Company, Limited Spink2 peptide for preventing and/or treating age-related macular degeneration
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JP2021500922A (ja) * 2017-10-20 2021-01-14 ジェミニ・セラピューティクス・インコーポレイテッドＧｅｍｉｎｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 加齢黄斑変性を処置するための組成物および方法
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
WO2019215330A1 (en) * 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration
EP3824095A4 (en) * 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
ES2974200T3 (es) * 2018-09-13 2024-06-26 Regeneron Pharma Rata nuligénica para el gen del factor H del complemento como modelo de glomerulopatía C3
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
KR20230019062A (ko) * 2019-10-22 2023-02-07 어플라이드 제네틱스 테크놀로지스 코퍼레이션 연령-관련 황반 변성 및 다른 안구 질환 및 장애의 치료를 위한 아데노-연관 바이러스 (aav) 벡터
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Variants of complement factor - 1 fusion structures and preparations containing them and their uses
AU2020454040B2 (en) 2020-06-19 2025-03-06 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
US11541039B2 (en) 2020-10-08 2023-01-03 Endogena Therapeutics, Inc. Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0451141B1 (en) 1988-05-20 1998-11-18 F. Hoffmann-La Roche Ag Immobilized sequence-specific probes
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8081491A (en) 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
EP0655090B1 (en) 1992-04-27 2000-12-27 The Trustees Of Dartmouth College Detection of gene sequences in biological fluids
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
CA2143848C (en) 1992-10-01 2007-09-11 W. Clark Still Complex combinatorial chemical libraries encoded with tags
JPH08505872A (ja) 1993-01-22 1996-06-25 ユニバーシティ・リサーチ・コーポレイション 治療剤の局所化
NZ276860A (en) 1993-11-02 1997-09-22 Affymax Tech Nv Apparatus and its use for synthesising diverse molecular products on substrates
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5959171A (en) 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1068311B2 (en) 1998-04-08 2020-12-09 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
US7312050B2 (en) 1998-10-29 2007-12-25 University Of Iowa Research Foundation Nucleic acids encoding interphotoreceptor matrix proteins
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
WO2001006262A1 (en) * 1999-02-19 2001-01-25 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
CA2363503C (en) * 1999-03-05 2009-03-10 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
CN1364780A (zh) * 2001-01-10 2002-08-21 上海博德基因开发有限公司 一种新的多肽——补体因子h12.32和编码这种多肽的多核苷酸
WO2002081638A2 (en) * 2001-04-06 2002-10-17 Origene Technologies, Inc Prostate cancer expression profiles
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
JP4772667B2 (ja) 2003-06-02 2011-09-14 エヴォルーテック・リミテッド 補体阻害剤
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7300471B2 (en) 2004-02-27 2007-11-27 L'oreal S.A. Composition comprising at least one mixed dye based on at least one chromophore of azo or tri(hetero) arylmethane type, dyeing process and mixed dyes.
PL2465534T3 (pl) * 2004-06-10 2017-08-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
WO2006062716A2 (en) * 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
EP2357257B1 (en) 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
CA2599080A1 (en) 2005-03-04 2006-09-14 Duke University Genetic variants increase the risk of age-related macular degeneration
AU2006220604A1 (en) 2005-03-07 2006-09-14 Board Of Regents, The University Of Texas System Diagnostic and therapeutic target for macular degeneration
AU2006254979B2 (en) 2005-06-08 2011-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
US20090220953A1 (en) 2005-08-24 2009-09-03 C.Y.O'connor Erade Village Foundation Identification of ancestral haplotypes and uses thereof
WO2007032876A2 (en) * 2005-09-09 2007-03-22 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) * 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
NZ574046A (en) * 2006-07-13 2012-09-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
EP2054728A2 (en) * 2006-08-23 2009-05-06 University of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
CA2704809A1 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
US7952830B2 (en) * 2009-06-04 2011-05-31 Samsung Electronics Co., Ltd. Method and apparatus for estimating flying height in a hard disk drive

Also Published As

Publication number Publication date
EP1856287B1 (en) 2011-09-28
EP2377951A1 (en) 2011-10-19
US11168120B2 (en) 2021-11-09
KR20130100207A (ko) 2013-09-09
IL225203A (en) 2015-07-30
CN103920142A (zh) 2014-07-16
CA2597411C (en) 2014-08-12
JP2012139228A (ja) 2012-07-26
NZ595305A (en) 2013-06-28
NZ608860A (en) 2014-10-31
US8497350B2 (en) 2013-07-30
US20130296255A1 (en) 2013-11-07
CA2597411A1 (en) 2006-08-24
EP1856287A2 (en) 2007-11-21
US20090124542A1 (en) 2009-05-14
HK1113176A1 (en) 2008-09-26
AU2006214320A1 (en) 2006-08-24
US20090247451A1 (en) 2009-10-01
AU2006214320C1 (en) 2012-07-05
IL185219A (en) 2013-11-28
EP2302076B1 (en) 2014-11-12
EP2302076A1 (en) 2011-03-30
HK1154634A1 (en) 2012-04-27
AU2006214320B2 (en) 2011-07-07
WO2006088950B1 (en) 2007-03-01
US20170369543A1 (en) 2017-12-28
US20090258822A1 (en) 2009-10-15
JP2008529536A (ja) 2008-08-07
US20160096871A1 (en) 2016-04-07
MX2007009565A (es) 2008-03-10
US20200165307A1 (en) 2020-05-28
KR20070112801A (ko) 2007-11-27
WO2006088950A3 (en) 2006-12-28
JP5100901B2 (ja) 2012-12-19
JP2012254089A (ja) 2012-12-27
US8088579B2 (en) 2012-01-03
JP2014204729A (ja) 2014-10-30
EP2357254A1 (en) 2011-08-17
US20070020647A1 (en) 2007-01-25
EP2357257B1 (en) 2019-07-31
WO2006088950A2 (en) 2006-08-24
US7745389B2 (en) 2010-06-29
EP2357257A1 (en) 2011-08-17
IL185219A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
ATE526421T1 (de) Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration
WO2008137236A3 (en) Treatment of age-related macular degeneration using inhibitors of complement factor d
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
EP1881823A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
EP1916964A4 (en) IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
EP1888786A4 (en) USE OF FREE CIRCULATION DNA FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
ATE536177T1 (de) Calixaren-basierte peptidkonformationsmimetika, verfahren zu ihrer verwendung und verfahren zu ihrer herstellung
DE602005014134D1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
EP1991274A4 (en) METHOD OF TREATMENT, PROPHYLAXIS AND DIAGNOSIS OF BONE PATHOLOGIES
EP2046807A4 (en) METHODS AND REAGENTS FOR THE TREATMENT AND DIAGNOSIS OF VASCULAR DISORDERS AND AGE-RELATED MACULAR DEGENERATION
DE602005008970D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
EP2139460A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE406801T1 (de) Verfahren zur herstellung von sauermilchprodukten
EP2046366A4 (en) METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE602006017995D1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
EP1869212A4 (en) USE OF ID4 TO DIAGNOSE AND TREAT CANCER
DE602005017373D1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
WO2007076437A3 (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties